Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression

International Journal of Cancer

Volumn 72, Issue 4, 1997, Pages 631-636

  Casalini, Patrizia ^a   Ménard, Sylvie ^a   Malandrin, Sergio M I ^a   Rigo, Cristina M ^a   Colnaghi, Maria I ^a   Cultraro, Constance M ^b   Segal, Shoshana ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL NAVAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG CARCINOMA; ONCOGENE C ERB; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; BASE SEQUENCE; CELL DIVISION; DNA, COMPLEMENTARY; GENE EXPRESSION; GENE THERAPY; GENES, ERBB-2; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES, ANTISENSE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 1842416594     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970807)72:4<631::AID-IJC14>3.0.CO;2-E     Document Type: Article

References (29)

1. AUSUBEL, P.M., BRENT, R., KINGSTON, R.E., MOORE, D.D., SEIDMAN, J.G., SMITH, J.A. and STRUHL, K., Current Protocols in Molecular Biology, Green and Wiley-Interscience, New York (1987).
2. BACUS, S.S., STANCOVSKI, I., HUBERMAN, E., CHIN, D., HURWITZ, E., MILLS, G.B., ULLRICH, A., SELA, M. and YARDEN, Y., Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res., 52, 2580-2589 (1992).
3. BYERS, V.S., LEVIN, A.S., WAITES, L.A., STARRETT, B.A., MAYER, R.A., CLEGG, J.A., PRICE, M.R., ROBINS, R.A., DELANEY, M. and BALDWIN, R.W., A Phase-I/II study of Trichosanthin treatment of HIV disease. AIDS, 4, 1189-1196 (1990).
4. CENTIS, F., TAGLIABUE, E., UPPUGUNDURI, S., PELLEGRINI, R., MARTIGNONE, S., MASTROIANNI, A., MÉNARD, S. and COLNAGHI, M.I., p185 HER2/neu epitope mapping with murine monoclonal antibodies. Hybridoma, 11, 267-276 (1992).
5. COLOMER, R., LUPU, R., BACUS, S.S. and GELMANN, E.P., erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Brit. J. Cancer, 70, 819-825 (1994).
6. COUSSENS, L., YANG-FENG, T.L., LIAO, Y.-C., CHEN, E., GRAY, A., MCGRATH, J., SEEBURG, P.H., LIBERMANN, F.A., SCHLESSINGER, J., FRANCKE, U., LEVINSON, A. and ULLRICH, A., Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-1139 (1985).
7. DESHANE, J., GRIM, J., LOECHEL, S., SIEGAL, G.P., ALVAREZ, R.D. and CURIEL, R.D., Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Therapy, 3, 89-98 (1996).
8. DI FIORE, P.P., PIERCE, J.H., KRAUS, M.H., SEGATTO, O., KING, C.R. and AARONSON, S.A., erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 237, 178-182 (1987).
9. D'SOUZA, B. and TAYLOR-PAPADIMITRIOU, J., Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. Proc. nat. Acad. Sci. (Wash.), 91, 7202-7206 (1994).
10. GUNNING, P., PONTE, P., OKAYAMA, H., ENGEL, J., BLAU, H. and KEDES, L., Isolation and characterization of full-length cDNA clones for human a-, b-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed. Mol. cell. Biol., 3, 787-795 (1983).
11. GUSTERSON, B.A. and 20 OTHERS. Prognostic importance of c-erbB-2 expression in breast cancer. J. clin. Oncol., 10, 1049-1056 (1992).
12. HÉLÈNE, C., Control of oncogene expression by antisense nucleic acids. Europ. J. Cancer [A], 30A, 1721-1726 (1994).
13. HYNES, N.E. and STERN, D.F., The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. biophys. Acta, 1198, 165-184 (1994).
14. KASID, U., PFEIFER, A., BRENNAN, T., BECKETT, M., WEICHSELBAUM, R.R., DRITSCHILO, A. and MARK, G.E., Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science, 243, 1354-1356 (1989).
15. KOOK, Y.H., ADAMSKI, J., ZELENT, A. and OSSOWSKI, L., The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J., 13, 3983-3991 (1994).
16. KRAUS, M.H., POPESCU, N.C., AMSBAUGH, S.C. and KING, C.R., Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J., 6, 605-610 (1987).
17. MÉNARD, S., PELLEGRINI, R., TOSI, E., SRINIVAS, U., POMPEN, M., CALDERA, M., CAMPIGLIO, M., MANENTI, G. and COLNAGHI, M.I., Oncogene products as targets for immunotherapy. In A.A. Epenetos (ed.): Monoclonal Antibodies 2: Applications in Clinical Oncology, pp. 227-231, Chapmann and Hall, London (1993).
18. MORONI, M.C., WILLINGHAM, M.C. and BÉGUINOT, L., EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. J. biol. Chem., 267, 2714-2722 (1992).
19. NECKERS, L., WHITESELL, L., ROSOLEN, A. and GESELOWITZ, D.A., Antisense inhibition of oncogene expression. Crit. Rev. Oncogenes, 3, 175-231 (1992).
20. PASLEAU, F., GROOTECLAES, M. and GOL-WINKLER, R., Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life. Oncogene, 8, 849-854 (1993).
21. PRESS, M.F., PIKE, M.C., CHAZIN, V.R., HUNG, G., UDOVE, J.A., MARKOWICZ, M., DANYLUK, J., GODOLPHIN, W., SLIWKOWSKI, M., AKITA, R., PATERSON, M.C. and SLAMON, D.J., Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res., 53, 4960-4970 (1993).
22. PUPA, M.S., MÉNARD, S., MORELLI, D., POZZI, B., DE PALO, G. and COLNAGHI, M.I., The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene, 8, 2917-2923 (1993).
23. STANCOVSKI, I., HURWITZ, E., LEITNER, O., ULLRICH, A., YARDEN, Y. and SELA, M., Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc. nat. Acad. Sci. (Wash.), 88, 8691-8695 (1991).
24. HER2 and growth inhibition of cells with HER2/neu gene amplification. Int. J. Cancer, 47, 933-937 (1991).
25. VAN DER KROL, A.R., MOL, J.N.M. and STUITJE, A.R., Modulation of eukaryotic gene expression by complementary RNA or DNA sequences. Biotechniques, 6, 958-976 (1988).
26. VAUGHN, J.P., IGLEHART, J.D., DEMIRDJI, S., DAVIS, P., BABISS, L.E., CARUTHERS, M.H. and MARKS, J.R., Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc. nat. Acad. Sci. (Wash.), 92, 8338-8342 (1995).
27. WRIGHT, C., NICHOLSON, S., ANGUS, B., CAIRNS, J., SAINSBURY, J.R.C., GULLICK, W.J., HARRIS, A.L. and HORNE, C.H.W., Association of c-erbB-2 oncoprotein expression with lack of response to endocrine therapy in recurrent breast-cancer. J. Pathol., 158, 350 (1989).
28. YU, D., SHI, D., SCANLON, M. and HUNG, M.-C., Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressine function of E1A. Cancer Res., 53, 5784-5790 (1993).
29. YU, D., SUEN, T.-C., YAN, D.-H., CHANG, L.-S. and HUNG, M.-C., Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc. nat. Acad. Sci. (Wash.), 87, 4499-4503 (1990).